NCT06875960View on ClinicalTrials.gov

A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

PHASE4RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 29, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2026

Conditions
Systemic Lupus Erythematosus (SLE)Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
Interventions
DRUG

BMS-986165

Specified dose on specified days

Trial Locations (3)

10155

RECRUITING

New York University School Of Medicine, New York

38305

WITHDRAWN

Local Institution - 0003, Jackson

06030

WITHDRAWN

Local Institution - 0001, Farmington

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY